ClinicalTrials.gg
CompletedNCT05268068Updated Mar 7, 2022

A Study of Intravenously (IV) Infused or Subcutaneously (SC) Injected Risankizumab in Healthy Adult Participants in China

A Phase 1 interventional study of Risankizumab and Risankizumab in Healthy Volunteers, sponsored by AbbVie. Completed at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-03-07.

Sponsored by AbbVie · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Registered 2 years 8 months after the study started (first participant enrolled Jun 2019, registered Mar 2022).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

The objective of this study to assess the pharmacokinetics, safety, tolerability and immunogenicity following a single subcutaneous (SC) or intravenous (IV) dose of risankizumab in healthy Chinese participants.

02

Conditions studied

  • Healthy Volunteers

Keywords

  • Healthy Volunteers
  • Risankizumab
  • ABBV-066
  • SKYRIZI
03

In context

Lead sponsor

AbbVie is the lead sponsor of 977 studies on the registry; 136 are open to participants now.

Of its 359 completed or terminated interventional studies of FDA-regulated products, 215 (60%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • (BMI) is >= 19.0 to \<= 26.0 kg/m2 after rounding to the nearest tenth. BMI is calculated as weight in kg divided by the square of height measured in meters.

Exclusion criteria

Exclusion Criteria:

  • Previous exposure to any anti-IL-12/23 or anti-IL-23 treatment.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    Dose A of Risankizumab for Subcutaneous (SC) Injection

    Participants will receive SC injections of risankizumab at dose A and then followed for 140 days.

    Drug: Risankizumab

  • Experimental
    Dose B of Risankizumab for Subcutaneous (SC) Injection

    Participants will receive SC injections of risankizumab at dose B and then followed for 140 days.

    Drug: Risankizumab

  • Experimental
    Dose C of Risankizumab for Intravenous (IV) Infusion

    Participants will receive IV infusion of risankizumab at dose C and then followed for 140 days.

    Drug: Risankizumab

Interventions

  • Intravenous (IV) Infusion

    Also known as: ABBV-066, SKYRIZI

  • Subcutaneous (SC) Injection

    Also known as: ABBV-066, SKYRIZI

06

What researchers measure

Primary outcomes

  1. Number of Participants with Adverse Events (AE)

    An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment.

    Time frame: Up to Approximately 140 Days

  2. Maximum Observed Concentration (Cmax)

    Maximum observed concentration.

    Time frame: Up to Approximately 140 Days

  3. Time to Cmax (Tmax)

    Time to Cmax.

    Time frame: Up to Approximately 140 Days

  4. Terminal Phase Elimination Rate Constant (β)

    Terminal phase elimination rate constant.

    Time frame: Up to Approximately 140 Days

  5. Terminal Phase Elimination Half-life (t1/2)

    Terminal phase elimination half-life.

    Time frame: Up to Approximately 140 Days

  6. Area Under the Concentration-Time Curve (AUC) from Time 0 to Time of the Last Measurable Concentration (AUCt)

    AUC from time 0 to time of the last measurable concentration (AUCt).

    Time frame: Up to Approximately 140 Days

  7. AUC from Time 0 to Infinity (AUCinf)

    AUC from time 0 to infinity (AUCinf).

    Time frame: Up to Approximately 140 Days

  8. Apparent Clearance (CL/F) for Subcutaneous (SC) dosing

    CL/F for SC dosing.

    Time frame: Up to Approximately 140 Days

  9. Clearance (CL) for Intravenous (IV) Dosing

    CL for IV dosing.

    Time frame: Up to Approximately 140 Days

  10. Number of Anti-drug antibody (ADA) Titers

    ADA titers will be tabulated for each participant at the respective study visits.

    Time frame: Up to Approximately 140 Days

07

Study locations

1 site
  • Shanghai Xuhui Central Hospital /ID# 212830
    Shanghai, Shanghai 200031, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2019 to primary completion in Apr 2020, 9 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 3, 2022
First posted
Mar 7, 2022
StartActual
Jun 27, 2019
Primary completionActual
Apr 26, 2020
CompletionActual
Apr 26, 2020
Last update
Mar 7, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 7, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05268068
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Mar 7, 2022
Start date
Jun 27, 2019
Primary completion
Apr 26, 2020
Completion
Apr 26, 2020
Last update
Mar 7, 2022

Study contacts

ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Risankizumab

Start the discussion